retatrutide parkinson parkinson's disease clinical trial Liraglutide once daily versus placebo in Parkinson's disease: a randomized, double Retatrutide 12.5mg + Cagrilintide 2.5mg

Medicare Advantage plans have the broadest discretion in formulary design, and in 2026 that variability is especially pronounced for GLP-1 drugs

GLP-1 receptor agonists seem to have the unique ability to reduce these effects without completely blocking dopamine release

-20C, 1 year

Interaction between noradrenergic and cholinergic signaling in amygdala regulates anxiety- and depression-related behaviors in mice

The winners will be brands that: Think GLP-1 compatible nutrition (not just weight loss) Deliver high-protein, low-volume, high-function formats Solve side effects + nutrient gaps (hydration, gut, muscle retention) Bridge food supplement beauty Hard truth: GLP-1 is accelerating trends we already knew: Protein is king Sugar is under attack Functionality beats indulgence Its just happening 10x faster now

The combination creates what researchers call preferential fat loss where the body is forced to derive nearly all of its energy from fat stores while protecting muscle